AZNCF Projected Dividend Yield
Ord/AstraZeneca Plc ( OTCBB : AZNCF )AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. 30 YEAR PERFORMANCE RESULTS |
AZNCF Dividend History Detail AZNCF Dividend News AZNCF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2025 |
N/A |
N/A |
Feb 21, 2025 |
Mar 24, 2025 |
2.1000 |
2025 Total: |
2.1000 |
||||
2024 |
N/A |
N/A |
Aug 09, 2024 |
Sep 09, 2024 |
1.0000 |
2024 |
N/A |
N/A |
Feb 23, 2024 |
Mar 25, 2024 |
1.9700 |
2024 Total: |
2.9700 |
||||
2023 |
N/A |
N/A |
Aug 11, 2023 |
Sep 11, 2023 |
0.9300 |
2023 |
N/A |
N/A |
Feb 24, 2023 |
Mar 27, 2023 |
1.9700 |
2023 Total: |
2.9000 |
||||
2022 |
N/A |
N/A |
Aug 12, 2022 |
Sep 12, 2022 |
0.9300 |
2022 |
N/A |
N/A |
Feb 25, 2022 |
Mar 28, 2022 |
1.9700 |
2022 Total: |
2.9000 |
||||
2021 |
N/A |
N/A |
Aug 13, 2021 |
Sep 13, 2021 |
0.9000 |
2021 |
N/A |
N/A |
Feb 26, 2021 |
Mar 29, 2021 |
1.9000 |
2021 Total: |
2.8000 |
||||
2020 |
N/A |
N/A |
Aug 14, 2020 |
Sep 14, 2020 |
0.9000 |
2020 |
N/A |
N/A |
Feb 28, 2020 |
Mar 30, 2020 |
1.9000 |
2020 Total: |
2.8000 |